Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.674 (95%CI: 0.517-0.800), 0.935 (95%CI: 0.888-0.963), 10.307 (95%CI: 6.167-17.227), 0.348 (95%CI: 0.226-0.537), and 29.582 (95%CI: 4.582-60.012), respectively. The AUC was 0.93 (95% CI: 0.90-0.95). The meta-analysis suggests that detection of EGFR mutation by cfDNA is of adequate diagnostic accuracy and cfDNA analysis could be a promising screening test for NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR mutations detected in plasma and urine have been shown to be concordant with those identified by tumor biopsy”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Noninvasive genotyping of cell-free plasma DNA (cfDNA) represents an attractive alternative for detection of EGFR T790M, noting that plasma genotyping for EGFR-sensitizing mutations is an established alternative in Europe when tumor genotyping is not feasible.19”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The diagnostic odds ratio: a single indicator of test performance
Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J., & Bossuyt, P. M. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00177-x · Cited by 2,261
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,169
Systematic Reviews of Diagnostic Test Accuracy
Leeflang, M. M. G., Deeks, J. J., Gatsonis, C., & Bossuyt, P. M. M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-12-200812160-00008 · Cited by 1,124
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 456
Yung, T. K. F., Chan, K. C. A., Mok, T. S. K., Tong, J., To, K.-F., & Lo, Y. M. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2622 · Cited by 385
Kimura, H., Kasahara, K., Kawaishi, M., Kunitoh, H., Tamura, T., Holloway, B., & Nishio, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2324 · Cited by 323
Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
Taniguchi, K., Uchida, J., Nishino, K., Kumagai, T., Okuyama, T., Okami, J., Higashiyama, M., Kodama, K., Imamura, F., & Kato, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1712 · Cited by 315
Bai, H., Mao, L., Wang, H. S., Zhao, J., Yang, L., An, T. T., Wang, X., Duan, C. J., Wu, N. M., Guo, Z. Q., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3930 · Cited by 273
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Kuang, Y., Rogers, A., Yeap, B. Y., Wang, L., Makrigiorgos, M., Vetrand, K., Thiede, S., Distel, R. J., & Jänne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 232
Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio, K., Itoh, Y., Jiang, H., Duffield, E., McCormack, R., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307f98 · Cited by 211
Kimura, H., Suminoe, M., Kasahara, K., Sone, T., Araya, T., Tamori, S., Koizumi, F., Nishio, K., Miyamoto, K., Fujimura, M., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603949 · Cited by 205
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer
Bai, H., Wang, Z., Chen, K., Zhao, J., Lee, J. J., Wang, S., Zhou, Q., Zhuo, M., Mao, L., An, T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3744 · Cited by 199
Cancer Screening in Theory and in Practice
Brawley, O. W., & Kramer, B. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.107 · Cited by 156
Liu, X., Lu, Y., Zhu, G., Yao, L., Li, Z., Qin, H., Tang, C., Ellison, G., McCormack, R., & Ji, Q. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201728 · Cited by 145
Espósito, A., Bardelli, A., Criscitiello, C., Colombo, N., Gelao, L., Fumagalli, L. A. M., Minchella, I., Locatelli, M., Goldhirsch, A., & Curigliano, G. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.003 · Cited by 125
Brevet, M., Johnson, M. L., Azzoli, C. G., & Ladanyi, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.014 · Cited by 120
Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer
Lara-Guerra, H., Waddell, T. K., Salvarrey, A. M., Joshua, A. M., Chung, C. T. ‐., Paul, N., Boerner, S. L., Sakurada, A., Ludkovski, O., Ma, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3370 · Cited by 117
He, C., Liu, M., Zhou, C., Zhang, J., Ouyang, M., Zhong, N., & Xu, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24653 · Cited by 111
Zhao, X., Han, R.-B., Zhao, J., Wang, J., Yang, F., Zhong, W., Zhang, L., Li, L.-Y., & Wang, M.-Z. (2013) · Respiration · doi:10.1159/000338790 · Cited by 107
Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
Kim, H.-R., Lee, S. Y., Hyun, D.-S., Lee, M. K., Lee, H.-K., Choi, C.-M., Yang, S.-H., Kim, Y.-C., Lee, Y. C., Kim, S. Y., et al. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-50 · Cited by 107
Giovannetti, E., Zucali, P. A., Peters, G. J., Cortesi, F., D’Incecco, A., Smit, E. F., Falcone, A., Burgers, J. A., Santoro, A., Danesi, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0665 · Cited by 76
Nakamura, T., Sueoka‐Aragane, N., Iwanaga, K., Sato, A., Komiya, K., Kobayashi, N., Hayashi, S., Hosomi, T., Hirai, M., Sueoka, E., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825f2821 · Cited by 75
Kimura, H., Kasahara, K., Shibata, K., Sone, T., Yoshimoto, A., Kita, T., Ichikawa, Y., Waseda, Y., Watanabe, K., Shiarasaki, H., et al. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31577-x · Cited by 67
Yeo, C. D., Kim, J. W., Kim, K. H., Ha, J. H., Rhee, C. K., Kim, S. J., Kim, Y. K., Park, C. K., Lee, S. H., Park, M. S., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.023 · Cited by 54
Zhang, H., Liu, D., Li, S., Zheng, Y.-Q., Yang, X., Li, X., Zhang, Q., Qin, N., Lu, J., Ren‐Heidenreich, L., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.06.006 · Cited by 52
Wang, X., Wang, X., Wang, X., Chen, F., Zhu, K., Xu, Q., & Tang, M. X. (2012) · Analytica Chimica Acta · doi:10.1016/j.aca.2012.12.037 · Cited by 52
Wang, S., Han, X., Hu, X., Wang, X., Zhao, L., Tang, L., Feng, Y., Wu, D., Sun, Y. P., & Shi, Y. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.12.026 · Cited by 49
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients
Yam, I., Lam, D. C.-L., Chan, K., Ho, J., Ip, M., Lam, W. K., Chan, T., & Chan, V. W. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182558198 · Cited by 47
Zhang, L., Xu, F., Wu, J., Xue, C., Zhao, Y., Jiang, W., Lin, L., Wu, X., Lu, Y., Bai, H., et al. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s37289 · Cited by 46
Jiang, B., Liu, F., Yang, L., Zhang, W., Yuan, H., Wang, J., & Huang, G. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900425 · Cited by 45
Hu, C., LIU, X., Chen, Y., Sun, X., Gong, Y., Geng, M., & Bi, L. (2012) · Oncology Reports · doi:10.3892/or.2012.1987 · Cited by 43
Huang, Z., Wang, Z., Bai, H., Wu, M., An, T., Zhao, J., Yang, L., Duan, J., Zhuo, M., Wang, Y., et al. (2012) · Thoracic Cancer · doi:10.1111/j.1759-7714.2012.00133.x · Cited by 42
Jing, C., Wang, Z., Cao, H., Ma, R., & Wu, J.-Z. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.11.6619 · Cited by 40
Kim, S. T., Sung, J. S., Jo, U., Park, K. H., Shin, S. W., & Kim, Y. H. (2013) · Medical Oncology · doi:10.1007/s12032-012-0328-3 · Cited by 33
Tiseo, M., Capelletti, M., Palma, G. D., Franciosi, V., Cavazzoni, A., Mozzoni, P., Alfieri, R. R., Goldoni, M., Galetti, M., Bortesi, B., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181861d67 · Cited by 31
Kim, S. T., Jung, H., Sung, J. S., Jo, U., Tanaka, T., Hagiwara, K., Park, K. H., Shin, S. W., Kim, J. S., & Kim, Y. H. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31823a5217 · Cited by 26
Lv, C., Ma, Y., Feng, Q. F., Fang, F., Bai, H., Zhao, B., Yan, S., Wu, N., Zheng, Q., Li, S., et al. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-96 · Cited by 18
Zhang, L., Yang, H., Zhao, Y., Liu, W., Wu, S., He, J., Luo, X., Zhu, Z., Xu, J., Zhou, Q., et al. (2012) · Current Drug Metabolism · doi:10.2174/138920012802138660 · Cited by 12
Li, L., Zhong, W., Liao, M., Chen, L., Han, B., Guan, Z., Yu, S., Liu, X., Wu, Y.-L. L. C., Jiang, G., et al. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.06.03 · Cited by 7
Bai, H., Zhao, J., Wang, S., An, T., Wang, X., Wu, M., Duan, J., Yang, L., Guo, Q., Liu, N.-H., et al. (2008) · PubMed · Cited by 6
Chen, S., Chen, Z. H., Guo, A., Su, J., Huang, Y., Chen, S., Zhang, X., Yang, X., Yang, J., & Wu, Y.-L. L. C. (2010) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2010.09.03 · Cited by 3
Cited by
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850
“Diagnostic Analysis Using the diagnostic analysis set (n = 216) with central tissue genotype as reference, sensitivity of plasma genotyping for the known sensitizing mutation was 82% for exon 19 deletions (112 of 136; 95% CI, 75% to 88%) and 86% for L858R (63 of 73; 95%CI, 76% to 93%; Table 1, Appendix Fig A2A, online…”
ResultLindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 645
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Metadata
- Authors
- Luo, J., Shen, L., & Zheng, D.
- Affiliations
- Tongji University (CN)
- Corresponding author
- Zheng, Di
- Venue
- Scientific Reports
- Published
- 2014-09-09
- Volume
- 4
- Issue
- 1
- Pages
- 6269-6269
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5385820
- OpenAlex
- W1979671400
- Cited by
- 212
- References
- 55
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 15 · 2022: 10 · 2021: 16 · 2020: 16 · 2019: 21 · 2018: 33 · 2017: 40 · 2016: 25 · 2015: 20
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- cell-free DNA, EGFR mutation, non-small cell lung cancer, liquid biopsy, diagnostic accuracy, EGFR tyrosine kinase inhibitors, tumor markers
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA, Female, Humans, Lung Neoplasms, Male, Mutation, Quinazolines, ROC Curve, Biomarkers, Tumor, Area Under Curve, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.